Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
Acute Myeloid Leukemia
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Sodium Bicarbonate Associated With Enhanced GVL Effect in AML Following Allo-HSCT
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Sociodemographic Characteristics a Strong Factor in EOL Healthcare Utilization in Acute Myeloid Leukemia
Researchers sought to determine how and which factors contribute to healthcare utilization by patients with AML at the end of life.
Combination Therapies With Venetoclax Preserved Health Status, QOL in Older Patients With AML
Comparison of results from 2 phase 3 studies of combination therapies are presented at ASH 2020.
Posttransplant Azacitidine for High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome
There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.
Poor COVID-19 Outcomes Among Patients With Hematologic Malignancies: Results From ECOVIDEHE
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
Gilteritinib-Azacitidine Tested in R/R FLT3-Mutated AML
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.
-
Loading...
-
Loading...
Next post in ASH 2020
